Allostera Pharma, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Allostera Pharma, Inc.
As emerging technologies begin to overcome peptide therapeutics’ pharmacologic limitations, their compelling potential grows clearer and their deal value has grown. Most if not all of Big Pharma and Big Biotech now have rebuilt their internal peptide drug development programs and show interest in start-ups with peptide pipelines and platforms.
A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions Database, providing comprehensive transaction coverage from 1991 to the present.
Start-Up showcases these recently launched companies: Allostera Pharma, Cabrelllis Pharmaceuticals, Kenta Biotech and ORTHOCON Inc.